Northwest Biotherapeutics to Open UK Clinic, Tackling Cancer Therapy Delays

BETHESDA, MD & LONDON, UK – April 21, 2026 – Northwest Biotherapeutics announced a significant strategic move today, revealing plans to establish its own dedicated leukapheresis clinic in London. The facility, located at the prestigious London Welbeck Hospital, is designed to directly address a critical bottleneck in the production of advanced immunotherapies, including the company's own DCVax treatments for solid tumor cancers. This proactive step aims to shorten patient wait times and secure a vital component of the company's supply chain as it moves closer to potential commercialization in the United Kingdom.

Addressing a Critical System-Wide Shortage

The decision to build a proprietary clinic stems from a growing, system-wide challenge within the UK's healthcare infrastructure. Leukapheresis, a specialized four-hour procedure to collect a patient's immune cells, is the essential first step for creating personalized cell therapies like CAR-T and dendritic cell vaccines. However, capacity for this procedure is failing to keep pace with the rapid growth of the advanced therapies sector.

Northwest Biotherapeutics (NWBio) stated it encountered these constraints firsthand through its compassionate use program, where patients faced "extended periods" waiting for an available appointment. For individuals with aggressive cancers like glioblastoma—the primary target of NWBio's lead candidate, DCVax-L—such delays can mean a deterioration of their clinical condition, potentially rendering them ineligible for treatment.

This issue is not unique to NWBio's experience. Reports from the UK's Advanced Therapy Treatment Centre (ATTC) network have highlighted that National Health Service (NHS) apheresis services are already operating at or near full capacity. Projections indicate a looming 25% increase in demand, driven by the pipeline of new Advanced Therapy Medicinal Products (ATMPs) nearing approval. NHS Blood and Transplant (NHSBT), which performs roughly half of all apheresis procedures in England and Wales, has also reported significant year-over-year growth in collections for CAR-T therapies and stem cell transplants, further straining existing resources. By establishing its own clinic, NWBio is taking direct control to insulate its patients from these systemic delays.

A Strategic Play for Supply Chain Control

The new clinic represents a calculated act of vertical integration, a strategic maneuver to de-risk the company's path to market. With its Marketing Authorization Application (MAA) for DCVax-L currently under review by UK regulators, ensuring a reliable and scalable source of starting material—the patient's own white blood cells—is paramount. Relying on third-party providers with limited availability would pose a significant operational risk, potentially throttling the company's ability to deliver treatment even if approval is granted.

The facility, located in London's renowned Harley Street medical district, is being built out in dedicated space within The London Welbeck Hospital, a private institution with a nearly 40-year history. NWBio began making plans and purchasing equipment in the final quarter of 2025, with the first leukapheresis machine already delivered and initial personnel selected. The buildout is slated for completion by June 2026.

Designed for both efficiency and growth, the clinic will initially be capable of performing procedures for four patients per day. The company has also built in flexibility to scale operations further through extended hours and weekend service as demand increases. This investment, coupled with ongoing expansions in its manufacturing capacity, demonstrates a concerted effort to build a robust internal foundation capable of supporting a significant volume of patients post-approval.

More Than a Clinic: A New Business Venture

While the primary mission of the clinic is to support NWBio's own therapeutic programs, the company has signaled broader commercial ambitions. The press release noted that the facility will "also enable provision of these services for other parties." This opens the door to a new revenue stream, positioning NWBio not just as a drug developer but also as a key service provider within the UK's burgeoning cell therapy ecosystem.

Many other biotechnology companies, both large and small, face the same leukapheresis capacity constraints. By offering its state-of-the-art services, NWBio could capture a new market and generate revenue independent of its own drug development timelines. This diversification could be a shrewd business move, providing financial stability and establishing the company as an integral infrastructure player in one of the world's leading hubs for life sciences.

The choice of the Harley Street location, while associated with higher operational costs, provides an unparalleled level of prestige and access to a global patient base seeking premium private medical care. The association with The London Welbeck Hospital lends immediate credibility and places the clinic at the heart of a district synonymous with medical excellence.

Navigating the Regulatory Gauntlet

Establishing and operating a specialized medical facility in the UK is a complex undertaking that requires navigating a multi-layered regulatory framework. NWBio confirmed that it is pursuing the necessary license applications in parallel with the clinic's construction, an ambitious timeline that underscores the urgency of the project.

Several key agencies must grant approval before the clinic can open its doors. The Care Quality Commission (CQC), the independent regulator of all health and social care services in England, will need to register the facility, a process that involves rigorous inspection of its premises, equipment, staffing, and standards of patient safety.

Furthermore, because the procedure involves the collection of human cells for therapeutic use, the clinic will fall under the purview of the Human Tissue Authority (HTA), which regulates the use and storage of human tissue. Finally, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the medical devices used, such as the apheresis machines, and holds ultimate authority over the manufacturing and administration of the final cell therapy products derived from the collections.

Successfully navigating these parallel approval processes is a critical hurdle. The company's proactive approach in initiating these applications early is essential to aligning the clinic's operational readiness with the completion of the physical build-out, aiming to prevent regulatory delays from creating a new bottleneck. The success of this initiative will ultimately depend on satisfying the stringent quality and safety standards set by these UK bodies, ensuring that the facility is not only ready but also fully compliant to serve its first patients.